{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:56:00Z","timestamp":1789584960177,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004505","name":"Universit\u00e0 degli Studi di Catania","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004505","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oncocytic adrenocortical carcinoma (OAC) is a rare variant of conventional adrenocortical carcinoma (ACC), characterized by oncocytic tumor cells comprising more than 90% of the tumor. Due to its rarity, there is a lack of reliable data on the clinicopathological features and outcomes of OAC. The aim of this study was to assess the clinical presentation, treatment modalities, and outcomes of patients with OAC, comparing these results with a cohort of patients with conventional ACC. Data from 9 referral centers in Italy on 44 patients with OAC were retrospectively analyzed and compared with data from 145 patients with conventional ACC. Patients with OAC had a smaller median tumor size, more favorable resection margin status, and lower incidences of venous invasion and persistent\/recurrent disease during follow-up. Additionally, patients with OAC exhibited longer times to progression (TTP) and overall survival (OS) compared to patients with conventional ACC. Multivariable analyses identified Ki67 and tumor size as features independently associated with disease progression during post-surgical follow-up, while Ki67 and distant metastases at diagnosis were independently associated with OS in OAC patients. After complete tumor removal, the risk of recurrent disease was higher in patients with either Ki67 \u2265\u200920% or ENSAT stage III\/IV. OAC appears to have a more indolent clinical course and better prognosis than conventional ACC. Similar to conventional ACC, Ki67 remains a significant prognostic marker for OAC and, along with ENSAT stage, serves as a reliable biomarker for identifying patients who may benefit from adjuvant mitotane therapy.<\/jats:p>","DOI":"10.1007\/s12022-025-09857-0","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T01:43:48Z","timestamp":1744335828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Multicentric Retrospective Analysis of Oncocytic Adrenocortical Carcinoma: Insights into Clinical and Management Strategies"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7021-9860","authenticated-orcid":false,"given":"Antonio","family":"Prinzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarnotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Di Dalmazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Canu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Ceccato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ferra\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Albertelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"De Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fanciulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Modica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Pani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Arcidiacono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Barca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Donnarumma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Zanatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Torchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ylenia","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Vitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Frasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasqualino","family":"Malandrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"9857_CR1","doi-asserted-by":"publisher","unstructured":"Berruti A, Baudin E, Gelderblom H, et al. (2012) Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23:vii131\u2013vii138. https:\/\/doi.org\/10.1093\/annonc\/mds231","DOI":"10.1093\/annonc\/mds231"},{"key":"9857_CR2","doi-asserted-by":"publisher","unstructured":"Kebebew E, Reiff E, Duh Q, et al (2006) Extent of Disease at Presentation and Outcome for Adrenocortical Carcinoma: Have We Made Progress? World J Surg 30:872\u2013878. https:\/\/doi.org\/10.1007\/s00268-005-0329-x","DOI":"10.1007\/s00268-005-0329-x"},{"key":"9857_CR3","doi-asserted-by":"publisher","unstructured":"Allolio B, Fassnacht M (2006) Adrenocortical Carcinoma: Clinical Update. J Clin Endocrinol Metab 91:2027\u20132037. https:\/\/doi.org\/10.1210\/jc.2005-2639","DOI":"10.1210\/jc.2005-2639"},{"key":"9857_CR4","doi-asserted-by":"publisher","unstructured":"Glenn JA, Else T, Hughes DT, et al (2019) Longitudinal patterns of recurrence in patients with adrenocortical carcinoma. Surgery 165:186\u2013195. https:\/\/doi.org\/10.1016\/j.surg.2018.04.068","DOI":"10.1016\/j.surg.2018.04.068"},{"key":"9857_CR5","doi-asserted-by":"publisher","unstructured":"Stigliano A, Chiodini I, Giordano R, et al (2016) Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE). J Endocrinol Invest 39:103\u2013121. https:\/\/doi.org\/10.1007\/s40618-015-0349-9","DOI":"10.1007\/s40618-015-0349-9"},{"key":"9857_CR6","doi-asserted-by":"publisher","unstructured":"Fassnacht M, Lib\u00e9 R, Kroiss M, Allolio B (2011) Adrenocortical carcinoma: a clinician\u2019s update. Nat Rev Endocrinol 7:323\u2013335. https:\/\/doi.org\/10.1038\/nrendo.2010.235","DOI":"10.1038\/nrendo.2010.235"},{"key":"9857_CR7","doi-asserted-by":"publisher","unstructured":"Fassnacht M, Dekkers OM, Else T, et al (2018) European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 179:G1\u2013G46. https:\/\/doi.org\/10.1530\/EJE-18-0608","DOI":"10.1530\/EJE-18-0608"},{"key":"9857_CR8","doi-asserted-by":"publisher","unstructured":"Lib\u00e9 R, Huillard O (2023) Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease. Cancer Treat Res Commun 37:100759. https:\/\/doi.org\/10.1016\/j.ctarc.2023.100759","DOI":"10.1016\/j.ctarc.2023.100759"},{"key":"9857_CR9","doi-asserted-by":"publisher","unstructured":"De Filpo G, Mannelli M, Canu L (2021) Adrenocortical carcinoma: current treatment options. Curr Opin Oncol 33:16\u201322. https:\/\/doi.org\/10.1097\/CCO.0000000000000695","DOI":"10.1097\/CCO.0000000000000695"},{"key":"9857_CR10","doi-asserted-by":"publisher","unstructured":"Puglisi S, Calabrese A, Basile V, et al (2020) New perspectives for mitotane treatment of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 34:101415. https:\/\/doi.org\/10.1016\/j.beem.2020.101415","DOI":"10.1016\/j.beem.2020.101415"},{"key":"9857_CR11","doi-asserted-by":"publisher","unstructured":"Mete O, Erickson LA, Juhlin CC, et al (2022) Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. Endocr Pathol 33:155\u2013196. https:\/\/doi.org\/10.1007\/s12022-022-09710-8","DOI":"10.1007\/s12022-022-09710-8"},{"key":"9857_CR12","doi-asserted-by":"publisher","unstructured":"Bisceglia M, Ludovico O, Di Mattia A, et al (2004) Adrenocortical Oncocytic Tumors: Report of 10 Cases and Review of the Literature. Int J Surg Pathol 12:231\u2013243. https:\/\/doi.org\/10.1177\/106689690401200304","DOI":"10.1177\/106689690401200304"},{"key":"9857_CR13","doi-asserted-by":"publisher","unstructured":"Wong DD, Spagnolo DV, Bisceglia M, et al (2011) Oncocytic adrenocortical neoplasms\u2014a clinicopathologic study of 13 new cases emphasizing the importance of their recognition. Hum Pathol 42:489\u2013499. https:\/\/doi.org\/10.1016\/j.humpath.2010.08.010","DOI":"10.1016\/j.humpath.2010.08.010"},{"key":"9857_CR14","doi-asserted-by":"publisher","unstructured":"Mills JK, Khalil M, Pasieka J, et al (2019) Oncocytic subtypes of adrenal cortical carcinoma: Aggressive in appearance yet more indolent in behavior? Surgery 166:524\u2013533. https:\/\/doi.org\/10.1016\/j.surg.2019.05.049","DOI":"10.1016\/j.surg.2019.05.049"},{"key":"9857_CR15","doi-asserted-by":"publisher","unstructured":"Shirali AS, Zagzag J, Chiang Y-J, et al (2022) Differences in Clinicopathologic Behavior of Oncocytic Adrenocortical Neoplasms and Conventional Adrenocortical Carcinomas. Ann Surg Oncol 29:5555\u20135563. https:\/\/doi.org\/10.1245\/s10434-022-11626-w","DOI":"10.1245\/s10434-022-11626-w"},{"key":"9857_CR16","doi-asserted-by":"publisher","unstructured":"Renaudin K, Smati S, Wargny M, et al (2018) Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation. Mod Pathol 31:1708\u20131716. https:\/\/doi.org\/10.1038\/s41379-018-0077-8","DOI":"10.1038\/s41379-018-0077-8"},{"key":"9857_CR17","doi-asserted-by":"publisher","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"9857_CR18","doi-asserted-by":"publisher","unstructured":"Weiss LM (1984) Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors: Am J Surg Pathol 8:163\u2013170. https:\/\/doi.org\/10.1097\/00000478-198403000-00001","DOI":"10.1097\/00000478-198403000-00001"},{"key":"9857_CR19","doi-asserted-by":"publisher","unstructured":"Weiss LM, Medeiros LJ, Vickery AL (1989) Pathologic Features of Prognostic Significance in Adrenocortical Carcinoma: Am J Surg Pathol 13:202\u2013206. https:\/\/doi.org\/10.1097\/00000478-198903000-00004","DOI":"10.1097\/00000478-198903000-00004"},{"key":"9857_CR20","doi-asserted-by":"publisher","unstructured":"Coppola Bottazzi E, Gambardella C, Mongardini FM, et al (2023) Prognosis of Adrenal Oncocytic Neoplasms (AONs): Literature Review of 287 Cases and Presentation of the Oldest Patient. J Clin Med 12:6925. https:\/\/doi.org\/10.3390\/jcm12216925","DOI":"10.3390\/jcm12216925"},{"key":"9857_CR21","doi-asserted-by":"publisher","unstructured":"Fewings E, Khoo Sert Kim S, Larionov A, et al (2021) Investigating the clinical, pathological and molecular profile of oncocytic adrenocortical neoplasms: a case series and literature review. Endocr Oncol 1:33\u201344. https:\/\/doi.org\/10.1530\/EO-21-0011","DOI":"10.1530\/EO-21-0011"},{"key":"9857_CR22","doi-asserted-by":"publisher","unstructured":"Puglisi S, Calabrese A, Ferra\u00f9 F, et al (2023) New Findings on Presentation and Outcome of Patients With Adrenocortical Cancer: Results From a National Cohort Study. J Clin Endocrinol Metab 108:2517\u20132525. https:\/\/doi.org\/10.1210\/clinem\/dgad199","DOI":"10.1210\/clinem\/dgad199"},{"key":"9857_CR23","doi-asserted-by":"publisher","unstructured":"Beuschlein F, Weigel J, Saeger W, et al (2015) Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. J Clin Endocrinol Metab 100:841\u2013849. https:\/\/doi.org\/10.1210\/jc.2014-3182","DOI":"10.1210\/jc.2014-3182"},{"key":"9857_CR24","doi-asserted-by":"publisher","unstructured":"Ohtake H, Kawamura H, Matsuzaki M, et al (2010) Oncocytic adrenocortical carcinoma. Ann Diagn Pathol 14:204\u2013208. https:\/\/doi.org\/10.1016\/j.anndiagpath.2009.06.006","DOI":"10.1016\/j.anndiagpath.2009.06.006"},{"key":"9857_CR25","doi-asserted-by":"publisher","unstructured":"Calabrese A, Puglisi S, Borin C, et al (2023) The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients. Eur J Endocrinol 188:118\u2013124. https:\/\/doi.org\/10.1093\/ejendo\/lvad002","DOI":"10.1093\/ejendo\/lvad002"},{"key":"9857_CR26","doi-asserted-by":"publisher","unstructured":"Daher M, Varghese J, Gruschkus SK, et al (2022) Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. J Clin Endocrinol Metab 107:1239\u20131246. https:\/\/doi.org\/10.1210\/clinem\/dgac046","DOI":"10.1210\/clinem\/dgac046"},{"key":"9857_CR27","doi-asserted-by":"publisher","unstructured":"Duregon E, Cappellesso R, Maffeis V et al (2017) Validation of the prognostic role of the \"Helsinki Score\u201d in 225 cases of adrenocortical carcinoma. Hum Pathol 62:1\u20137. https:\/\/doi.org\/10.1016\/j.humpath.2016.09.035","DOI":"10.1016\/j.humpath.2016.09.035"},{"key":"9857_CR28","doi-asserted-by":"publisher","unstructured":"Duregon E, Volante M, Cappia S, et al (2011) Oncocytic Adrenocortical Tumors: Diagnostic Algorithm and Mitochondrial DNA Profile in 27 Cases. Am J Surg Pathol 35:1882\u20131893. https:\/\/doi.org\/10.1097\/PAS.0b013e31822da401","DOI":"10.1097\/PAS.0b013e31822da401"},{"key":"9857_CR29","doi-asserted-by":"publisher","unstructured":"Hodgson A, Pakbaz S, Mete O (2019) A diagnostic approach to adrenocortical tumors. Surg Pathol Clin 12:967\u2013995. https:\/\/doi.org\/10.1016\/j.path.2019.08.005","DOI":"10.1016\/j.path.2019.08.005"},{"key":"9857_CR30","doi-asserted-by":"publisher","unstructured":"Volante M, Bollito E, Sperone P, et al (2009) Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology 55:535\u2013543. https:\/\/doi.org\/10.1111\/j.1365-2559.2009.03423.x","DOI":"10.1111\/j.1365-2559.2009.03423.x"},{"key":"9857_CR31","doi-asserted-by":"publisher","unstructured":"Giordano TJ, Berney D, De Krijger RR, et al (2021) Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Hum Pathol 110:50\u201361. https:\/\/doi.org\/10.1016\/j.humpath.2020.10.001","DOI":"10.1016\/j.humpath.2020.10.001"},{"key":"9857_CR32","doi-asserted-by":"publisher","unstructured":"Ragazzon B, Lib\u00e9 R, Gaujoux S, et al (2010) Transcriptome Analysis Reveals that p53 and \u03b2-Catenin Alterations Occur in a Group of Aggressive Adrenocortical Cancers. Cancer Res 70:8276\u20138281. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2014","DOI":"10.1158\/0008-5472.CAN-10-2014"},{"key":"9857_CR33","doi-asserted-by":"publisher","unstructured":"Zheng S, Cherniack AD, Dewal N, et al (2016) Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell 29:723\u2013736. https:\/\/doi.org\/10.1016\/j.ccell.2016.04.002","DOI":"10.1016\/j.ccell.2016.04.002"},{"key":"9857_CR34","doi-asserted-by":"publisher","unstructured":"Riedmeier M, Decarolis B, Haubitz I, et al (2021) Adrenocortical Carcinoma in Childhood: A Systematic Review. Cancers 13:5266. https:\/\/doi.org\/10.3390\/cancers13215266","DOI":"10.3390\/cancers13215266"},{"key":"9857_CR35","doi-asserted-by":"publisher","unstructured":"Pereira SS, Monteiro MP, Costa MM, et al (2019) IGF2 role in adrenocortical carcinoma biology. Endocrine 66:326\u2013337. https:\/\/doi.org\/10.1007\/s12020-019-02033-5","DOI":"10.1007\/s12020-019-02033-5"},{"key":"9857_CR36","doi-asserted-by":"publisher","unstructured":"Mete O, Gucer H, Kefeli M, Asa SL (2018) Diagnostic and Prognostic Biomarkers of Adrenal Cortical Carcinoma. Am J Surg Pathol 42:201\u2013213. https:\/\/doi.org\/10.1097\/PAS.0000000000000943","DOI":"10.1097\/PAS.0000000000000943"},{"key":"9857_CR37","doi-asserted-by":"publisher","unstructured":"Fassnacht M, Assie G, Baudin E, et al (2020) Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO\u2013EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1476\u20131490. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2099","DOI":"10.1016\/j.annonc.2020.08.2099"}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09857-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12022-025-09857-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09857-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:25:50Z","timestamp":1767860750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12022-025-09857-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9857"],"URL":"https:\/\/doi.org\/10.1007\/s12022-025-09857-0","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"2 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance to the Declaration of Helsinki and received approval from the Institutional Review Board and Ethical Committee Catania 2 in Sicily, Italy (approval no. 63\/CEL).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11"}}